Gabriel-Medina, Pablo http://orcid.org/0000-0003-3079-6364
Ferrer-Costa, Roser
Ciudin, Andreea
Augustin, Salvador
Rivera-Esteban, Jesus
Pericàs, J. M.
Selva, D. M.
Rodriguez-Frias, Francisco
Article History
Received: 2 December 2022
Accepted: 21 June 2023
First Online: 11 November 2023
Declarations
:
: Juan M. Pericàs: Consulting, speaking and travel fees (Boehringer-Ingelheim, MSD, Novo Nordisk, Gilead, Intercept, Rubió, Pfizer, Astellas, CUBICIN, Novartis), Educational and research support (Madrigal, Novo Nordisk, Gilead, Pfizer, Astellas, Accelerate, Novartis, Abbvie, ViiV, and MSD. Funds from European Commission/EFPIA IMI2 853966-2, IMI2 777377, H2020 847989, ISCIII PI19/01898 and PI22/01770). Salvador Augustin: Consulting / Advisory Boards (Boehringer Ingelheim, Gilead, Intercept, Novartis, Pfizer, Ferrer, IQVIA), Speaking fees (Allergan, Gilead, MSD, Menarini, Novartis, Allergan), Grants (Gilead). Rest of authors declare no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional (approved by the local Ethics Committee (PR(AG)601/2020)) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Vall d’Hebron University Hospital (protocol code PR(AG)601/2020 signed on 17 March 2021).
: Informed consent was obtained from all subjects involved in the study.